IP-10 AS A PREDICTOR OF TREATMENT RESPONSE IN CHRONIC HEPATITIS C PATIENTS.

  • Hepato-Gastroenterology, National Liver Institute, Menoufia University, Shebin El-Kom, Menoufia, Egypt.
  • Clinical and Chemical Pathology department, National Liver Institute, Menoufia University, Shebin El-Kom, Menoufia, Egypt.
Crossref Cited-by Linking logo

  • Abstract
  • References
  • Cite This Article as
  • Corresponding Author

Background & Aim: Hepatitis C virus (HCV) is a globally prevalent pathogen and a leading cause of death and morbidity. IFN-gamma inducible protein 10 kDa (IP-10, or CXCL10), predict a more pronounced first phase decline of HCV RNA during anti-viral therapy. We assessed pretreatment serum IP-10 as a predictor of SVR in treated chronic HCV. Subjects and methods: Seventy adult chronic HCV patients were included in the prospective controlled study and 10 healthy subjects as a control group. All patients were treated with combined pegylated interferon and ribavirin therapy: pegylated IFN-?2b, 1.5 µg/kg/week or pegylated IFN-?2a, 180 µg/week SC plus ribavirin (15mg/kg/day orally) for 48 weeks and were followed up for 6 months later. Results: There was statistically significant difference between the Non-SVR group and SVR group as regards IP10 level (395 ±167.9 vs. 159.9 ±55.2) pg/ml; AFP level (7.2 ±11.4 vs. 3.8 ±1.8) ng/ml and Liver Stiffness measurement by transient elastography (10.9 ±6.3 vs. 7.4 ±2.5) kpa, respectively. On multivariate regression analysis for predictors of post-treatment SVR: IP10 was the only independent predictor of achieving SVR (Odds=0.97; C.I 95%= 0.95-0.99; P=0.002). At cutoff point for IP10 more than 216.6 pg/ml has a sensitivity of 90%, specificity 87.5%, PPV 84.4% and NPV 92.1% at P = 0.001; C.I 95% = 0.900-1.000 to define patients with SVR. Conclusion: Pretreatment IP-10 level should be included as a predictor of SVR. Attempts to neutralize IP-10 or block IP-10 receptor should be considered as additional strategies to improve the outcome of the antiviral therapy.

  1. Abdoul H, Mallet V, Pol S, Fontanet A (2008): Serum alpha-fetoprotein predicts treatment outcome in chronic hepatitis C patients regardless of HCV genotype. PLoS One; 3: e2391.
  2. Andersen E, Christensen P and Weis N ( 2009): Transient elastography for liver fibrosis diagnosis. Euro J Intern Med; 20 (4): 339- 342.
  3. Alexopoulou & Karayiannis (2015): Interferon-based combination treatment for chronic hepatitis C in the era of direct acting antivirals. Gastroenterol.; 28 (1):55-65.
  4. Adnan U, Mirza T, Aziz S, Naz E (2013): Histomorphological changes in hepatitis C non-responders with respect to viral genotypes. J Pak Med Assoc; 63 :448-453.
  5. Antonucci G, Longo MA, Angeletti C, Vairo F, Oliva A, et al. (2007): The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV Hepatitis including subjects older than 65 yr. Am J Gastroenterol 102: 1383-1391.
  6. Apolinario A, Majano PL, Lorente R, , Núñez O, Clemente G, García-Monzón C (2005). Gene expression profile of T cell specific chemokines in human hepatocyte-derived cells: Evidence for a synergistic inducer effect of cytokines and hepatitis C virus J Viral Hepat; 12: 27–37.
  7. Askarieh G, Alsio A, Pugnale P, Negro F, Ferrari C, et al. (2010) Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. Hepatology 51: 1523–1530.
  8. Assad NY, Ehsan NA, Abdou AG, El-Tahmody MA, El-Sabaawy MM, El-Naidany NF, El-Kholy SS (2014): The impact of clinicopathological parameters in predicting response to pegylated interferon and ribavirin in chronic hepatitis C patients. Menoufia Med J; 27:785-92.
  9. Asselah T, Marcellin P (2013): Interferon free therapy with direct acting antivirals for HCV. Liver Int 33: 93-104.
  10. Bedossa P and Poynard T (1996): An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology; 24(2): 289-93.
  11. Casrouge A, et al (2011). Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J Clin Invest.;121(1):308–317
  12. Codes et al, (2007): Liver fibrosis in women with chronic hepatitis C: evidence for the negative role of the menopause and steatosis and the potential benefit of hormone replacement therapy. Gut. ; 56:390–395.
  13. Cuadros DF, Branscum AJ, Miller FD, et al (2014): Spatial epidemiology of hepatitis C virus infection in Egypt: Analyses and implications, Hepatology; 51:1122–1126.
  14. Charles, E.D., Dustin, L.B. (2011): Chemokine antagonism in chronic hepatitis C virus infection. J. Clin. Invest. 121, 25–27.
  15. Chattergoon MA, Levine JS, Latanich R, Osburn WO, Thomas DL, Cox AL. (2011): High plasma interleukin-18 levels mark the acute phase of hepatitisC virus infection. J. Infect. Dis.; 204:1730–40.
  16. Dabeva MD and Shafritz DA (1993): Activation, proliferation, and differentiation of progenitor cells into hepatocytes in the D-galactosamine model of liver regeneration. Am J Pathol.; 143:1606–20.
  17. Di Marco, L. Covolo, V. Calvaruso, M. Levrero, M. Puoti, F. Suter, et al (2013): Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysisJ Viral Hepat, 20 pp. 790–800.
  18. Diago M, Castellano G, Garc?a-Samaniego J, Perez C, Fer-nandez I, Romero M, Iacono OL, Garc?a-Monzon C. (2006): Association of pretreatment serum interferon gamma induc-ible protein 10 levels with sustained virological response topeginterferon plus ribavirin therapy in genotype 1 infectedpatients with chronic hepatitis C. Gut 55:374–379.
  19. Dore, G. J. (2012): The changing therapeutic landscape for hepatitis C. Med. J. Aust. 196, 629–632.
  20. European Association for the study of the Liver consensus panel (2012): European Association for the study of Liver International consensus conference on hepatitis C. J Hepatol.; 30:956-61.
  21. El Makhzangy H, Esmat G, Said M, Elraziky M, Shouman S,Refai R, Rekacewicz C, Gad RR, Vignier N, Abdel-Hamid M,Zalata K, Bedossa P, Pol S, Fontanet A, Mohamed MK. (2009): Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4. J Med Virol 81(9):1576–1583.
  22. El Raziky M et al, (2015): IP 10 Serum Level in Chronic Hepatitis C Virus Patients:Relation to Fibrosis and Response to Combined Interferon/Ribavirin Therapy Journal of interferon and cytokine research Aug, 35(8):649.
  23. Everson G.T., Hoefs J.C., Seeff L.B., Bonkovsky H.L., Naishadham D., Shiffman M.L. et al. (2006): Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C trial. Hepatology; 44:1675–1684.
  24. Falconer K, Askarieh G, Weis N, Hellstrand K, Alaeus A, Lagging M. (2010): IP10 predicts the first phase decline of HCV RNA and overall viral response to therapy in patients co-infected with chronic hepatitis C virus infection and Scand J Infect Dis.; 42:896-901.
  25. Fattovich G, Covolo L, Bibert S, Askarieh G, Lagging M, et al. (2011): IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic Hepatitis C. Aliment Pharmacol Ther 33: 1162-1172.
  26. Ferenci P (2004): Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies. J Antimicrob Chemother.; 53: 15–18.
  27. Fried MW (2002): Side effects of therapy of hepatitis C and their management. Hepatology; 36: S237–44.
  28. Gad, R.R., Males, S., El Makhzangy, H., Shouman, S., Hasan, A., Attala, M. et al. (2008): Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C. Liver Int.; 28: 1112–1119.
  29. Ghany MG, Strader DB, Thomas DL et al. (2009): Diagnosis, Management and treatment of hepatitis C: An Update. Hepatology; 49:1335-74.
  30. Guerra J, Garenne M, Mohamed MK, Fontanet A. (2012): HCV burden of infection in Egypt: results from a nationwide survey. J Viral Hepat 19(8):560–567.
  31. Hadziyannis SJ, Sette H Jr, Morgan TR et al. (2004): Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med.; 140: 346–55.
  32. Hraber P, Kuiken C, Yusim K. (2007): Evidence for human leukocyte antigen heterozygote advantage against hepatitis C virus infection. Hepatology; 46:1713-1721.
  33. Kasztelan-Szczerbiñska B, S³omka M, Celiñski K, Szczerbiñski M (2003): Impact of interferon-alpha therapy on the serum level of alpha-fetoprotein in patients with chronic viral hepatitis. Rocz Akad Med Bialymst; 48:74-77.
  34. Kau A, Vermehren J, Sarrazin C. (2008): Treatment predictors of a sustained virologic response in hepatitis B and C. J. Hepatol.; 49(4), 634–651.
  35. Larrubia JR, Benito-Martinez S, Calvino M, et al. (2008): Role of chemokines and their receptors in viral persistence and liver damage during chronic hepatitis C virus infection. World J Gastroenterol.; 14(47):7149-59.
  36. Males et al (2007): Serum alpha foetoprotein level predicts treatment outcome in chronic hepatitis C. Antiviral Therapy; 12:797–803.
  37. Martinez et al (2012): Longitudinal liver stiffness assessment in patients with chronic hepatitis C undergoing antiviral therapy. PLoS One; 7 e47715
  38. Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, et al. (2010): An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 139: 821–827, 827 e821.
  39. Matsuura K., et al (2014): Serum interferon-gamma-inducible protein-10 concentrations and IL28B genotype associated with responses to pegylated interferon plus ribavirin with and without telaprevir for chronic hepatitis C. Hepatol Res; 44(12):1208-1216.
  40. Mitchell, et al, (2010) recommendations for the prevention and control of hepatitis B and C. Hepatology; 51(3), 729–733.
  41. Mohd, et al (2013): Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology.; 57:1333–1342.
  42. Moreno C, Hezode C, Marcellin P, et al. (2015): Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4. J Hepatol.;62:1047-55
  43. Ogawa E,Furusyo N,Murata M, et al. (2012): insulin resistance undermines the advantages of IL28B Polymorphism in the pegylated interferon alpha -2b and ribavirin treatment of chronic hepatitis Cpatients with genotype 1Journal of hepatology;57:534-540.
  44. Omran D1, Hamdy S, Tawfik S, Esmat S, Saleh DA, Zayed RA (2014): Association of interferon-? inducible protein-10 pretreatment level and sustained virological response in HCV-positive Egyptian patients .Ann Clin Lab Sci. Spring; 44(2):167-72.
  45. Poynard T, McHutchison J., Goodman Z., Ling M.H., Albrecht J. (2000): Is an ‘a la carte' combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology; 31:211–218.
  46. Poynard T., McHutchison J., Manns M., et al. (2002): Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology; 122:1303-13.
  47. Rauch A, Kutalik Z,Descombes P, et al. (2010).Genetic variation inIL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology; 138: 1338–45.
  48. Reddy K, Rakela J, Lopez-Talavera J et al. (2005): Correlations between rapid virological  response, early virological response and sustained virological  response in HCV genotype 1 patients treated with pegylated  interferon  alfa-2a  and  Abstract S1540. Digestive Disease Week, May 14–18. Chicago, IL.
  49. Reiberger T, Aberle JH, Kundi M, Kohrgruber N, Rieger A,Gangl A, Holzmann H, Peck-Radosavljevic M. (2008): IP-10 correlates with hepatitis C viral load, hepatic inflammation andfibrosis and predicts hepatitis C virus relapse or non-responsein HIV-HCV coinfection. Antivir Ther.; 13(8):969–976.
  50. Romero AI, Lagging M,Westin J, et al.(2006): Interferon (IFN)-gamma inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis; 194: 895–903.
  51. Schuppan, D.; Krebs, A.; Bauer, M.; Hahn, E. G. (2003): Hepatitis C and liver fibrosis, Cell Death Differ, 10, S59-S67.
  52. Sievert W, Altraif I, Razavi H, et al. (2011): A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int;31 (Suppl 2):61-80.
  53. Stasi et al. (2015): Evaluation of the prognostic value of liver stiffness in patients with hepatitis C virus treated with  triple  or  dual  antiviral therapy: Aprospective pilot study. World J Gastroenterol, 21(10): 3013-3019.
  54. Thomas, D. L. (2010).Curing hepatitis C with pills-A step toward global control. Lancet; 376, 1441-1442.
  55. Thompson AJ, Muir AJ, Sulkowski MS, et al. (2010): Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in hepatitis C virus-1 patients. Gastroenterology; 139: 120–9, e18.
  56. Wan L, Kung YJ, Lin YJ, et al. (2009): Th1 and  Th2  cytokines  are  elevated  in HCV-infected  SVRa patients  treated  with  interferon-alpha.  Biochem Biophys Res Commun.; 379:855-60.
  57. Yoneda S, Umemura T, Joshita S, Ichijo T, Matsumoto A, et al. (2011): Serum chemokine levels are associated with the outcome of pegylated interferon and ribavirin therapy in patients with chronic Hepatitis C. Hepatol Res 41: 587-593.
  58. Zeremski M, Petrovic LM, Chiriboga L, Brown QB, Yee HT, et al. (2008): Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology. 48: 1440–1450 doi:10.1002/hep.22500.

[Nabil Omar, Khalid Gamil, Mohamed Abdel-Samiee and Mary Naguib. (2017); IP-10 AS A PREDICTOR OF TREATMENT RESPONSE IN CHRONIC HEPATITIS C PATIENTS. Int. J. of Adv. Res. 5 (Mar). 752-766] (ISSN 2320-5407). www.journalijar.com

Mohamed Abdel-Samiee
PHD

DOI:

Article DOI: 10.21474/IJAR01/3568      
DOI URL: https://dx.doi.org/10.21474/IJAR01/3568

Download Full Paper

Download PDF No. of Downloads: 11 | No. of Views: 80